---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046860"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:26.156937+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

## Summary
- SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.
- No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.
- Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.
- Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.
- Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations.

## SEC filing metadata
- accession: 0001628280-24-046860
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/0001628280-24-046860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/syre-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046860
- JSON: https://secwatch.observer/filing/0001628280-24-046860.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.